Bristol Myers Squibb Stock Jumps On An Unexpectedly Good Delay

Bristol Myers Squibb (BMY) stock popped Wednesday after the drugmaker delayed the results of a study testing its Cobenfy in patients with Alzheimer’s disease psychosis. The delay is due to irregularities in enrollment at several clinical trial sites, William Blair analyst Matt Phipps said in a report. Bristol needs more time to enroll additional patients. The company expects to have…